Vaxart, Inc. (VXRT) stock prices were up by 6.84% as of the market closing on June 7th, 2021, bringing the price per share up to USD$7.34 at the end of the trading day. Subsequent pre-market fluctuations have seen the stock rise by 4.22%, bringing it up to USD$7.65.
First Patient Enrolled
The company announced on May 4th, 2021 that it had enrolled the first subject in its Phase 1b boosting regiment trial for it norovirus vaccine candidate. The study is designed to facilitate the evaluation of the safety and immunogenicity of various dosing intervals for the company’s proprietary drug candidate. The treatment being developed is the only clinical stage norovirus oral tablet vaccine currently being developed.
The estimated cost of the negative economic impact of the norovirus in the U.S. was pegged at USD$10.5 billion annually in a health economic study published in the American Journal of Preventative Medicine in January of 2021. Annual vaccine costs, assuming an efficacy rate of 75%, were cost effective and saved on expenses in the amounts of up to USD$1600 and USD$1300 per year in preschool-aged children. Annual savings came out to an upper limit of USD$165 and USD$100 for older adults.
Scope of Treatment
Almost 20 million Americans are infected by the potentially fatal Norovirus disease every year, with 15% of children under the age of five reporting being infected every year in the United States alone. Its proliferation is significant enough to warrant a designation of norovirus as a priority disease by the World Health Organization for its accelerated vaccine development. With no currently available approved vaccine available, the major health problem translated into a multi-billion dollar annual impact in the U.S, and significantly more beyond its borders.
Details about the Trial
The ongoing study will serve to provide insight into the optimal booster timing in order to facilitate the maximum possible immunogenicity and total response of the oral norovirus vaccine candidate. Furthermore, VXRT hopes the findings can shed important light on the overall dynamics of its platform technology that could guide potential protocols for other vaccine candidates. Included in these candidates is the company’s oral Covid-19 tablet vaccine candidate, which is forecasted to enter Phase 2 clinical trials around the middle of fiscal 2021.
Future Outlook for VXRT
Having initiated the enrollment of human patients for its clinical trial for the treatment of norovirus, VXRT is poised to capitalize on the opportunities to develop the treatment through to commercialization. With such a massive unaddressed market, the company is keen to continue and improve its trajectory of success over the next several quarters. Current and potential investors are hopeful that management will leverage the resource at their disposal to facilitate significant and sustained increases in shareholder value.